# Blood Thinner May Slow Cognitive Decline in Alzheimer's Patients With AFib
Researchers have found that anticoagulant medications, commonly prescribed to prevent stroke in people with atrial fibrillation, may also slow cognitive decline in Alzheimer's disease patients. The discovery offers a potential new avenue for protecting brain health in this vulnerable population.
Atrial fibrillation, or AFib, affects the heart's rhythm and significantly increases stroke risk. Blood thinners like warfarin and direct oral anticoagulants prevent dangerous clots. Now evidence suggests these drugs may offer dual benefits for older adults facing both conditions simultaneously.
The connection appears rooted in how these medications work. Anticoagulants reduce clot formation throughout the body, including in brain vessels. Small strokes from clots are a known contributor to cognitive decline. By preventing these micro-clots, blood thinners may protect brain cells from cumulative damage that accelerates Alzheimer's progression.
This matters because roughly 10 percent of Alzheimer's patients also have AFib. These individuals face a compounded threat to cognition from both degenerative disease and stroke-related damage. Current Alzheimer's treatments like lecanemab slow decline but work only in early stages and require complex infusions.
The research doesn't suggest blood thinners treat Alzheimer's directly. Rather, they may reduce one specific pathway of cognitive decline. Patients with both conditions should not start or stop anticoagulants based on this finding alone. AFib treatment decisions remain driven by stroke prevention needs, which typically outweigh other considerations.
For families managing Alzheimer's in relatives with AFib, the research suggests that staying compliant with prescribed anticoagulants offers broader protection than previously recognized. Doctors already recommend these medications for AFib patients. This new evidence